Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FNTA | P49354 | 7/20 | 0.48 |
| ▸ | FNTB | P49356 | 5/20 | 0.48 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.44 |
| ▸ | BTN3A1 | O00481 | 1/20 | 0.43 |
| ▸ | PGGT1B | P53609 | 2/20 | 0.42 |
| ▸ | GGPS1 | O95749 | 4/20 | 0.42 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22235275 | 0.89 | BTN3A1 (0.54) | FNTAFNTBALOX15BTN3A1PGGT1B | |
| SCHEMBL6690483 | 0.89 | BTN3A1 (0.54) | FNTAFNTBALOX15BTN3A1PGGT1B | |
| SCHEMBL394658 | 0.81 | FNTA (0.65) | FNTAFNTBPGGT1BGGPS1 | |
| SCHEMBL6694732 | 0.78 | ALOX15 (0.41) | FNTAFNTBALOX15BTN3A1NFE2L2 | |
| SCHEMBL6689625 | 0.77 | ALOX15 (0.60) | FNTAFNTBALOX15BTN3A1GGPS1 | |
| SCHEMBL28326977 | 0.77 | ALOX15 (0.47) | ALOX15BTN3A1NFE2L2 | |
| Hydrochloric Acid SCHEMBL6698170 | 0.76 | ALOX15 (0.58) | FNTAFNTBALOX15BTN3A1GGPS1 | |
| SCHEMBL6700613 | 0.74 | FNTA (0.42) | FNTAFNTBALOX15BTN3A1PGGT1B | |
| SCHEMBL27969320 | 0.74 | BTN3A1 (0.43) | FNTAFNTBBTN3A1 | |
| SCHEMBL31236132 | 0.73 | BTN3A1 (0.67) | FNTAFNTBBTN3A1PGGT1BGGPS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040180813-A1 | 4-Amino acid functionalized-2-pyrophosphatyl-pyranes; direct assay, high throughput screening for enzyme inhibitors; N-acetylglucosaminyltransferase | THE TRUSTEES OF PRINCETON UNIVERSITY | 2004-09-16 | — | — | US | disclosed |
| US-6703213-B2 | ENZYME INHIBITOR FOR USE IN THE TREATMENT AND PREVENTION OF BACTERIAL INFECTIONS | THE TRUSTEES OF PRINCETON UNIVERSITY | 2004-03-09 | — | — | US | disclosed |
| US-20020182661-A1 | Substrate analogs for MurG, methods of making same and assays using same | TRUSTEES OF PRINCETON UNIVERSITY, THE | 2002-12-05 | — | — | US | disclosed |
| EP-1053305-A4 | SUBSTRATE ANALOGS FOR MurG, METHODS OF MAKING SAME AND ASSAYS USING SAME | UNIV PRINCETON (US) | 2002-08-21 | — | — | EP | disclosed |
| US-6413732-B1 | N-ACETYLGLUCOSAMINYL-URIDINE DIPHOSPHATE (UDP); MONITORING N-ACETYLGLUCOSAMINYL TRANSFERASE INVOLVED IN BACTERIAL CELL WALL BIOSYNTHESIS; ANTIBIOTICS, BACTERICIDES | THE TRUSTEES OF PRINCETON UNIVERSITY | 2002-07-02 | — | — | US | disclosed |
| EP-1053305-A1 | SUBSTRATE ANALOGS FOR MurG, METHODS OF MAKING SAME AND ASSAYS USING SAME | Princeton University (US) | 2000-11-22 | — | — | EP | disclosed |
| WO-1999038958-A9 | SUBSTRATE ANALOGS FOR MurG, METHODS OF MAKING SAME AND ASSAYS USING SAME | UNIV PRINCETON (US) | 1999-10-14 | — | — | WO | disclosed |
| WO-1999038958-A1 | SUBSTRATE ANALOGS FOR MurG, METHODS OF MAKING SAME AND ASSAYS USING SAME | PRINCETON UNIVERSITY (US) | 1999-08-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040180813-A1 | 4-Amino acid functionalized-2-pyrophosphatyl-pyranes; direct assay, high throughput screening for enzyme inhibitors; N-acetylglucosaminyltransferase | DPAGT1, MAGT1, OGT | FNTA 52/4885FNTB 112/4885ALOX15 1048/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.